SeaStar Medical Holding (ICU) AI Stock Analysis

• Market Cap: $12.12M
• Dividend Yield: N/A
• Average Volume (3M): 198.24K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.85
• Revenue Growth: N/A
• EPS Growth: 75.26%
• Country: US
• Employees: 19
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -7.59
• Shares Outstanding: 8,721,036
• 10 Day Avg. Volume: 276,385
• 30 Day Avg. Volume: 198,243
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 145.71
• Price to Cash Flow (P/CF): -0.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.00
• Price Target Upside: 418.52% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

SeaStar Medical faces significant financial challenges with ongoing losses and negative equity, which are major risks. While the FDA approval for the QUELIMMUNE device is a positive development, it is not enough to offset the financial instability. Technical indicators show mixed signals, and valuation remains difficult due to negative earnings. Strategic improvements in financial health are crucial for sustainable growth.

Positive Factors

Market Expansion

ICU's ability to engage pediatric hospitals and achieve a 70% conversion rate is encouraging for the company's growth prospects.

Product Development

SeaStar is on track to finalize patient enrollment and submit for pre-market approval for adult AKI indications, which is seen as a significant near-term catalyst.

Regulatory Approval

The FDA approval and commercial launch of the QUELIMMUNE device for pediatric patients with AKI due to sepsis have been significant milestones for SeaStar.

Technological Potential

The company’s recent Breakthrough Device Designation from the FDA for its SCD for adults with chronic dialysis supports optimism regarding the technology’s potential in treating several indications.

Negative Factors

Financial Performance

ICU reported lower revenue and higher operational expenses than expected, indicating potential financial challenges.

Stock Price Target

Due to share dilution from an expected capital raise and slightly lower estimates, the 12-month price target is reduced to $7, from $18.

SeaStar Medical Holding Business Overview & Revenue Model

Company Description

SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.

How the Company Makes Money

SeaStar Medical Holding makes money through the sale and licensing of its Selective Cytopheretic Device (SCD) to hospitals, healthcare providers, and potentially through partnerships with other medical technology companies. Revenue is primarily generated from the commercialization of its patented therapies targeting acute kidney injury and other inflammatory conditions. The company may also derive income from ongoing research and development collaborations and potential future expansions into additional therapeutic areas.

SeaStar Medical Holding Financial Statement Overview

Summary

SeaStar Medical is in a precarious financial position with ongoing profitability challenges and negative equity. The introduction of revenue in 2024 is a positive sign but overshadowed by high operational losses and reliance on external financing.

Income Statement

The income statement reveals significant challenges. The company reported its first revenue in 2024, but the gross profit margin is low, and the net profit margin is negative due to substantial losses. EBIT and EBITDA margins are also negative, indicating ongoing operational struggles. Although there is a revenue introduction, past years show no revenue, and the trajectory needs monitoring.

Balance Sheet

The balance sheet shows financial instability with negative stockholders' equity, indicating potential solvency issues. The debt-to-equity ratio cannot be calculated due to negative equity, which is a significant concern. Total liabilities exceed total assets, and the equity ratio is negative, suggesting poor financial health and high financial risk.

Cash Flow

Cash flow analysis indicates strained liquidity with no free cash flow and operating cash flow issues. The operating cash flow to net income ratio is negligible, reflecting difficulty in converting revenue to cash. Financing cash flow is positive, indicating reliance on external financing to sustain operations, which is risky if not managed well.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
68.00K	135.00K	0.00	0.00	0.00	0.00
	Gross Profit
68.00K	135.00K	0.00	0.00	0.00	0.00
	EBIT
-16.02M	-17.84M	-14.21M	-11.61M	-4.45M	-6.45M
	EBITDA
-29.59M	-17.84M	-11.14M	-11.61M	0.00	0.00
	Net Income Common Stockholders
-30.29M	-24.83M	-26.23M	-23.01M	-4.60M	-3.28M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
503.31K	1.82M	176.00K	47.00K	510.00K	2.81M
	Total Assets
106.83M	4.66M	3.51M	4.77M	603.00K	2.91M
	Total Debt
0.00	574.00K	9.08M	8.83M	2.62M	83.00K
	Net Debt
-503.31K	-1.25M	8.90M	8.78M	2.11M	-2.72M
	Total Liabilities
10.20M	6.84M	17.38M	13.00M	76.77M	74.49M
	Stockholders Equity
96.64M	-2.18M	-13.87M	-8.23M	-76.17M	-71.58M
Cash Flow		Free Cash Flow
-15.80M	0.00	-10.29M	-7.79M	-5.11M	-5.57M
	Operating Cash Flow
-15.80M	0.00	-10.29M	-7.79M	-5.11M	-5.57M
	Investing Cash Flow
0.00	0.00	0.00	0.00	-105.57M	0.00
	Financing Cash Flow
17.81M	17.65M	10.41M	7.33M	2.82M	4.89M

SeaStar Medical Holding Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ICU, the sentiment is Negative. The current price of 1.35 is below the 20-day moving average (MA) of 1.94, below the 50-day MA of 1.85, and below the 200-day MA of 3.93, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.55 is Neutral, neither overbought nor oversold. The STOCH value of 8.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ICU.

SeaStar Medical Holding Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDGL	54 Neutral	$7.15B	―	-80.35%	―	―	-10.89%
AKBA	49 Neutral	$491.11M	―	91.25%	―	-17.75%	-19.17%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
BLRX	48 Neutral	$11.39M	―	-184.09%	―	―	68.50%
CARA	44 Neutral	$22.64M	―	-270.01%	―	-65.96%	40.80%
APRE	38 Underperform	$10.54M	―	-66.65%	―	157.63%	40.52%
ICU	35 Underperform	$12.12M	―	1475.93%	―	―	75.26%

SeaStar Medical Holding Corporate Events

SeaStar Medical Secures $6M Through Equity Agreements

On January 31, 2025, SeaStar Medical Holdings entered a Securities Purchase Agreement with an institutional investor, issuing shares and warrants in both a registered direct offering and a concurrent private placement, expecting gross proceeds of approximately $6 million. The funds are intended for general corporate purposes, potentially impacting its operational capabilities and market strategy by enhancing working capital and capital expenditures.

SeaStar Medical Gains FDA Approval for Pediatric Device

SeaStar Medical announced the FDA approval of its QUELIMMUNE device for pediatric acute kidney injury, marking a significant milestone in its commercialization strategy. The company is currently enrolling patients in a pivotal trial for adult acute kidney injury, a market significantly larger than the pediatric segment. This progress underscores SeaStar’s potential to capture a substantial share of the multibillion-dollar market for inflammation-driven diseases, leveraging its proven SCD platform technology.